Non-exclusive drug rebate agreement for Naloxegol
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Naloxegol (ATC-Code nach WHO: A06AH03)
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No guaranteed volume or minimum purchase; actual revenue may be negligible.
The buyer may terminate the Open-House early if exclusive agreements are concluded, leading to termination of existing...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jul 31, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jul 2027
- Non-exclusive pharmaceutical rebate agreement for Naloxegol
- Drug supply to AOK PLUS insured members in Saxony and Thuringia
Show full summary
This tender from AOK PLUS is a non-exclusive pharmaceutical rebate agreement for the active substance Naloxegol (ATC A06AH03) under § 130a Abs. 8 SGB V, using an Open-House model. It is not a traditional public procurement; it is published for transparency. Any qualified pharmaceutical company can join by accepting the terms. No minimum volumes, no exclusivity, and no individual negotiations. The agreement ends 31 July 2027. The estimated value is not disclosed, and the volume is unknown. This is a framework-like arrangement with rolling submission deadlines.
Risks
No guaranteed volume or minimum purchase; actual revenue may be negligible.
The buyer may terminate the Open-House early if exclusive agreements are concluded, leading to termination of existing...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company (pharmazeutischer Unternehmer) as per §4 Abs. 18 AMG, with seat in Germany, EU, or EEA
Eligibility
- Must submit completed declaration on exclusion grounds (§§123,124 GWB)
Administrative
- Must submit declaration on Russia sanctions compliance
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive drug rebate agreement for Naloxegol
Conclusion of non-exclusive rebate agreements for Naloxegol within an Open-House model. The buyer reserves the right to terminate early if exclusive agreements are concluded.
Location
Duration
Category
Award Criteria
Deadline
Award details
No award criteria specified
the notice states that award criteria fields are technical placeholders due to the form used.
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Naloxegol (ATC-Code nach WHO: A06AH03)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 29 May 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 350276-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No guaranteed volume or minimum purchase; actual revenue may be negligible.
The buyer may terminate the Open-House early if exclusive agreements are concluded, leading to termination of existing...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications